Monoclonal-antibody for analysis and clearance of polyethylene glycol and polyethylene glycol-modified molecules
US6596849B1 · kind B1 · utility
8Cited by
0References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 7, 2000 |
| Grant date | Jul 22, 2003 |
| Priority date | — |
| Expiry date | Mar 7, 2020 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2430/60
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A novel anti-polyethylene glycol monoclonal antibody and its preparation are disclosed. Such an antibody can be used for determining polyethylene glycol concentration in vitro or accelerating the clearance of a polyethylene glycol containing compound from the blood circulation in the human body thereby reducing the toxicity associated with the polyethylene glycol containing conjugate. The antibody is particularly useful in cancer therapy where the therapeutic agent is selectively delivered to the tumor by increasing the tumor/blood ratio of the polyethylene glycol containing compound.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.